|1.||Flatt, P R: 10 articles (02/2015 - 07/2007)|
|2.||Irwin, N: 9 articles (02/2015 - 07/2007)|
|3.||Holst, Jens J: 7 articles (10/2015 - 01/2002)|
|4.||Lacroix, A: 6 articles (07/2004 - 02/2000)|
|5.||N'Diaye, N: 5 articles (07/2004 - 02/2000)|
|6.||Gault, V A: 4 articles (02/2015 - 07/2007)|
|7.||Hamet, P: 4 articles (07/2004 - 10/2000)|
|8.||Montgomery, I A: 3 articles (08/2013 - 09/2010)|
|9.||Harada, Norio: 3 articles (01/2013 - 12/2007)|
|10.||Yamane, Shunsuke: 3 articles (01/2013 - 12/2007)|
|1.||Body Weight (Weight, Body)
12/07/2007 - "Gastric inhibitory polypeptide (GIP) is known to promote efficient storage of ingested nutrients into adipose tissue; we examined aging-associated changes in body composition using 10-week-old and 50-week-old wild-type (WT) and GIP receptor knockout (Gipr-/-) mice on a normal diet, which show no difference in body weight. "
01/01/1981 - "Gastric inhibitory polypeptide (GIP) release into the portal vein in response to duodenal instillation of glucose in doses of 0.695, 1.39, 2.78 and 5.56 mmol/kg body weight was studied in an acute condition in male Wistar rats. "
09/01/1980 - "The gastric inhibitory polypeptide response after a sucrose load (2 g/kg body weight) was significantly greater (P < 0.01) after th subjects consumed the sucrose rather than the starch diet. "
06/19/2009 - "Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are major incretins associated with body weight regulation. "
08/01/2013 - "Body weight, glucose parameters, responses of plasma glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and gastric inhibitory polypeptide (GIP) to 75 g glucose were measured at baseline and 3 months after surgery. "
01/01/1988 - "In this in vitro human model, pancreatic polypeptide cell secretion was inhibited by hyperglycemia, although the presence of gastric inhibitory polypeptide augmented the pancreatic polypeptide cell response. "
02/01/1986 - "Gastric inhibitory polypeptide (GIP) has insulinotropic actions in the presence of hyperglycemia. "
04/01/2009 - "We examined whether acute hyperglycemia reduces the postprandial excursions of gastric inhibitory polypeptide (GIP) and GLP-1, and if so, whether this can be attributed to changes in gastric emptying. "
04/01/2009 - "Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans."
01/01/1988 - "Perfusion with low levels of insulin and splanchnic nerve stimulation augmented the response of the pancreatic polypeptide cell to hyperglycemia and gastric inhibitory polypeptide. "
07/14/2012 - "The effects of active immunisation with gastric inhibitory polypeptide (GIP) or (proline3)GIP-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy expenditure and cognition were examined in high-fat-fed mice. "
07/14/2012 - "Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice."
08/01/2011 - "The presence of functional gastric inhibitory polypeptide (GIP) receptors on adipocytes and knowledge that GIP plays a key role in fat deposition suggests a beneficial effect of GIP receptor antagonism in obesity and insulin resistance. "
02/01/2009 - "Insulin resistance was induced by 24 h pretreatment with 10(-7) m insulin, causing a marked reduction in activation of Akt and ERK1/2. Furthermore, both insulin-induced GLP-1 release and secretion in response to glucose-dependent insulinotropic peptide and phorbol-12-myristate-13-acetate were significantly attenuated. "
02/01/2012 - "Glucose-dependent insulinotropic polypeptide [also known as gastric inhibitory polypeptide (GIP)] and its receptor (GIPR) may link overnutrition to obesity, insulin resistance, and type 2 diabetes. "
01/01/1987 - "In order to clarify the role of gastric inhibitory polypeptide (GIP) in an enteroinsular axis, 19 healthy mongrel dogs were divided into following groups: 5 normal dogs (N), 4 dogs with gastrojejunostomy (GJ), 5 dogs with duodenal fistula (D) and 5 vagotomized dogs (V). "
10/01/1981 - "To determine whether gastric inhibitory polypeptide (GIP) promotes the clearance of chylomicron triglycerides (TG) from the circulation in dogs, chyle collected from donor dogs via a thoracic duct fistula was infused at a rate of 2 ml/min i.v. into normal recipient dogs during an infusion of either porcine GIP (1 microgram/kg per h) or saline as a control. "
03/01/1989 - "The purpose of this investigation was to examine the effect of PYY on gastric inhibitory polypeptide (GIP)-stimulated insulin release in conscious dogs with gastric and duodenal fistulas. "
11/01/1982 - "The effect of sham feeding on the plasma concentration of gastric inhibitory polypeptide (GIP) was studied in unrestrained rats bearing chronic gastric fistulas and jugular catheters. "
11/01/1982 - "The inhibition of gastrin 17-stimulated acid secretion by a partially purified cholecystokinin preparation (PcB) containing 1.2% cholecystokinin and 0.7% gastric inhibitory polypeptide immunoreactivity was compared with the inhibition produced by immunopurified cholecystokinin, cholecystokinin-depleted PcB, and gastric inhibitory polypeptide in 6 dogs with gastric fistulas. "
|5.||Weight Loss (Weight Reduction)
11/01/2007 - "Exaggerated postprandial GLP-1 and blunted glucose-dependent insulinotropic peptide secretion after RYGB might contribute to the greater weight loss and improved glucose homeostasis compared with BND."
05/01/1981 - "Major factors may include decreased absorption of carbohydrates and amino acids, decreased oral caloric intake, increased insulin sensitivity and decreased output of gastric inhibitory polypeptide as well as the eventual weight loss."
07/01/2013 - "We describe mechanisms of action for combinations of glucagon-like peptide 1, glucagon, gastric inhibitory polypeptide, gastrin, islet amyloid polypeptide and leptin, which enhance weight loss whilst preserving glucoregulatory efficacy in experimental models of obesity and T2DM. "
10/27/2011 - "One year after the initial weight loss, there were still significant differences from baseline in the mean levels of leptin (P<0.001), peptide YY (P<0.001), cholecystokinin (P=0.04), insulin (P=0.01), ghrelin (P<0.001), gastric inhibitory polypeptide (P<0.001), and pancreatic polypeptide (P=0.002), as well as hunger (P<0.001). "
10/27/2011 - "Weight loss (mean [±SE], 13.5±0.5 kg) led to significant reductions in levels of leptin, peptide YY, cholecystokinin, insulin (P<0.001 for all comparisons), and amylin (P=0.002) and to increases in levels of ghrelin (P<0.001), gastric inhibitory polypeptide (P=0.004), and pancreatic polypeptide (P=0.008). "
|3.||Glucagon-Like Peptide 1 (GLP 1)
|5.||Blood Glucose (Blood Sugar)
|6.||Glucagon-Like Peptides (Enteroglucagon)
|7.||gastric inhibitory polypeptide receptor
|10.||Pro(3)- glucose-dependent insulinotropic polypeptide
|5.||Enteral Nutrition (Feeding, Tube)